Clinuvel success in Scenesse trial
19 December, 2012 by Tim DeanClinuvel (ASX:CUV) has shown in a phase IIa trial that its Scenesse implant in combination with UV therapy can aid in the treatment if skin pigmentation condition vitiligo.
Biotech bites: Sirtex to be listed on S&P/ASX 200
18 December, 2012 by Tim DeanSirtex Medical (ASX:SRX) will be added to the S&P/ASX 200 after Integra Mining Limited (ASX:IGR) was dropped from the list.
Annual global biopharmaceutical manufacturing survey is on again
18 December, 2012 by AusBiotechBiopharmaceutical manufacturers and contract manufacturing organisations (CMOs) are invited to participate in the bio-industry's most in-depth, global study: the 10th Annual Biopharmaceutical Manufacturing Report and Survey.
Invion to submit IND for lupus treatment in 2013
17 December, 2012 by Tim DeanFollowing a pre-IND meeting with the FDA that set the roadmap for clinical trials for its lupus treatment, Invion (ASX:IVX) will file an IND early next year.
Bionomics progressing with Alzheimer's drug
14 December, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has chosen an Alzheimer's treatment candidate from its alpha-7 programme, and is preparing for both clinical trials and a potential industry partnership.
ABCA gathers for Council’s inaugural meeting
13 December, 2012 by AusBiotechThe first meeting of the Agricultural Biotechnology Council of Australia (ABCA) took place in Canberra last week, signalling a new and significant era for Australian agriculture.
Alchemia in final stages of demerger
13 December, 2012 by Tim DeanAlchemia (ASX:ACL) has entered a trading halt as it is on the cusp of completing its demerger and spin-off of Audeo Oncology, which prepares for its IPO.
AusBiotech comments on FSANZ cost recovery plans for health claims applications
11 December, 2012 by AusBiotechAusBiotech has written to Food Standards Australia New Zealand (FSANZ) in response to its consultation on proposed cost recovery arrangements for applications related to health claims, opposing the move.
National nanotechnology strategy looks to boost biotech
07 December, 2012 by Tim DeanThe Australian Academy of Science’s National Nanotech Research Strategy aims to boost investment and research in nanotech, including in nanobiotechnology and nanomedicine.
Starpharma's anti-cancer docetaxel beats Taxotere in animals
06 December, 2012 by Dylan Bushell-EmblingAnimal trials of Starpharma (ASX:SPL) dendrimer-docetaxel showed a significant reduction in tumour cell survival compared to original formula Taxotere.
Trans Tasman joint therapeutic products scheme progresses
06 December, 2012 by AusBiotechProgress towards a joint Australia New Zealand therapeutic products regulatory scheme continues with the second meeting of the Australia New Zealand Therapeutic Products Agency (ANZTPA) Implementation Ministerial Council last week.
Sirtex to investigate nanoparticle anti-cancer technology
05 December, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has entered a research collaboration with Singapore's SingHealth to explore the applications of Carbon Gage Nanoparticles in combating difficult-to-treat cancers.
CSL rebrands Australian businesses
05 December, 2012 by Tim DeanIconic Australian biotech, CSL, is rebranding its two core business units covering plasma and pharmaceuticals in line with a company global reorganisation.
Biotech Christmas celebrations continue around the country
04 December, 2012 by AusBiotechWhile some states have already begun Christmas celebrations, three states are about to host AusBiotech's free Christmas events as their final networking events of 2012.
Osprey enrols first patient for diabetic limb recovery trial
04 December, 2012 by Dylan Bushell-EmblingOsprey Medical (ASX:OSP) has signed up the first of a planned 25 patients for an Australian trial of its Limb Recovery System in diabetic patients with limb infections.
